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Background: Clarithromycin (CLR) is the key drug in eradication therapy of Helicobacter pylori (H. pylori) infection,
and widespread use of CLR has led to an increase in primary CLR-resistant H. pylori. The known mechanism of
CLR resistance has been established in A2146G and A2147G mutations in the 23S rRNA gene, but evidence of the
involvement of other genetic mechanisms is lacking. Using the MiSeq platform, whole-genome sequencing of the
19 clinical strains and the reference strain ATCC26695 was performed to identify single nucleotide variants (SNVs) of
multi-drug resistant efflux pump genes in the CLR-resistant phenotype.
Results: Based on sequencing data of ATCC26695, over one million sequencing reads with over 50-fold coverage
were sufficient to detect SNVs, but not indels in the bacterial genome. Sequencing reads of the clinical isolates
ranged from 1.82 to 10.8 million, and average coverage ranged from 90.9- to 686.3-fold, which were acceptable
criteria for detecting SNVs. Utilizing the conventional approach of allele-specific PCR, point mutations in the 23S
rRNA gene were detected in 12 clinical resistant isolates, but not in 7 clinical susceptible isolates. All sequencing
reads of CLR-resistant strains had a G mutation in an identical position of the 23S rRNA gene. In addition, genetic
variants of four gene clusters (hp0605-hp0607, hp0971-hp0969, hp1327-hp1329, and hp1489-hp1487) of TolC
homologues, which have been implicated in multi-drug resistance, were examined. Specific SNVs were dominantly
found in resistant strains.
Conclusions: Gene clusters of TolC homologues are involved in CLR susceptibility profiles in individual H. pylori
strains. Whole-genome sequencing has yielded novel understanding of genotype-phenotype relationships.
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Helicobacter pylori (H. pylori) infection is recognized in
approximately 50% of the adult population and associated
with a wide range of upper gastrointestinal diseases [1,2].
Present treatments for H. pylori infection consist of a
proton pump inhibitor based triple therapy in combination* Correspondence: tana@kobepharma-u.ac.jp
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unless otherwise stated.with amoxicillin and clarithromycin (CLR) [2]. Triple
therapy has remained the first-choice regimen for the
past decade and has been recommended by most
consensus meetings, and by both European and American
scientific societies [3-6].
In many cases, CLR is the key component of eradication
therapy, but antibiotic resistance is the primary failure
of triple therapy in patients with H. pylori infection. Preva-
lence of CLR-resistant H. pylori has become increasingly
common in many countries [7,8]. Consequently, it has
been suggested that the efficacy of standard triple therapy
has been gradually reduced to unacceptable levels [9]. It isal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Representative electrophoresis patterns of allele-specific
PCR products. PCR products were amplified with mixed primers for
determination of A2146G and A2147G mutations in 23S rRNA of H. pylori.
PCR products of 320 bp are commonly observed for the H. pylori 23S
rRNA gene. PCR products of 238 or 240 bp indicate the presence of a
point mutation in the 23S rRNA gene. PCR products were obtained from
ATCC26695 (lane 1), J99 (lane 2), and five representative CLR-resistant
strains (lanes 3–7; S1, S13, S17, S26, and 174). The 100 bp marker ladder is
indicated by M.
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H. pylori infection when the prevalence of CLR resistance
is higher than 15–20% [3]; in such cases, other therapeutic
alternatives should be considered.
CLR binds to the peptidyl transferase region of the
bacterial 23S rRNA and inhibits protein synthesis [10].
Acquired resistance of CLR in H. pylori has been associated
with point mutations in the peptidyl transferase region of
domain V of the 23S rRNA. Two copies of the 23S rRNA
gene are present in H. pylori, and the most common
mutation is an A-to-G transition at position 2146 and 2147
(previously known as A2142G and A2143G) [11]. Recent
reports have also indicated that other 23S rRNA gene
mutations might be associated with CLR resistance [12,13].
In addition, CLR resistance seems to be related with other
factors, such as rRNA methylase production [14], the
actions of macrolide-inactivating enzymes, and active efflux
pumps, which have been described in several bacterial
species [15]. Indeed, an active efflux pump has been shown
to contribute to CLR resistance in H. pylori [16]. As a result
of the worldwide increased rate of CLR resistance, some
studies have indicated that other bacterial genetic factors
might contribute to this increased resistance [17,18].
However, there is no genetic evidence for other bacterial
factors in H. pylori.
To characterize the bacterial pathogen samples, recent
advances in whole-genome sequencing, such as the
development of DNA-sequencing technologies, were
applied to this study [19]. Compared to conventional
methods (e.g., capillary sequencing and non-sequence-
based molecular methods), next-generation sequencing
provides deep views on bacterial genome information
without biases in downstream analysis [20]. These
techniques are the ideal tool to comprehensively track
extensive genomic knowledge of antimicrobial resist-
ance and to facilitate specific and rational treatment
of infected patients [21]. However, despite the broad
advantages, next-generation sequencing requires the
extensive bioinformatics tasks for data analysis from
assembly to gene annotation, and this remains a sig-
nificant problem for the routine application to clinical
microbiology [22].
In this study, we first applied the established method
of allele-specific PCR to detect 23S rRNA gene mutations
in clinical H. pylori strains and identified CLR-resistant
isolates. To elucidate the unidentified genetic factors
in the reduced susceptibility to CLR in H. pylori,
whole-genome sequencing was applied to 20 selected
H. pylori strains, including the major laboratory strain
ATCC26695, 12 resistant and 7 susceptible strains. Of
note, we focused on variants of multidrug resistance
(MDR) efflux pumps that contribute to both intrinsic
and acquired antibiotic resistance and assessed their
association with novel mechanisms of CLR resistance.Results
AS-PCR for A2146G and A2147G mutations in 23S rRNA
For 19 clinical isolates, AS-PCR clearly differentiated the
23S rRNA mutants from the H. pylori (Figure 1). Point
mutations in the 23S rRNA gene at position 2146 or 2147
were detected in 12 strains and defined as CLR-resistant
isolates in this study. Twelve mutant strains were iso-
lated from patients who failed eradication therapy,
and 7 wild-type strains were isolated from patients
with successful eradication therapy. Thus, AS-PCR results
were in agreement with the outcome of eradication therapy
based on clinical information (data not shown).
ATCC26695 total reads and average coverage
Prior to analysis of clinical isolate sequencing data, we
generated six independent sequencing data sets from
ATCC26695 to determine the adequate total reads and
average coverage that should be targeted for our study
(Table 1). Illumina MiSeq generated 150-bp paired-end
reads with 110,650 to 2,148,576 reads from the six
samples. After trimming, the number of total reads was
nearly unchanged before trimming. When all data were
mapped to the theoretical nucleotide length of ATCC26695
(1,667,867 bp) using Genomics Workbench 6.0.1, the total
consensus coverage (%) ranged from 87.38 to 99.99%,
and average coverage was from 4.2- to 81.7-fold. In the
sequencing data from sample 5 and 6, each with over one
million reads, we found nearly equal total consensus
coverage (99.98 and 99.99%, respectively) and average
coverage (71.8- and 81.7-fold, respectively).
Table 1 Six ATCC26695 sequence data sets














1 110,650 109,952 1,457,400 87.38 4.2 210,467 NA
2 130,226 130,216 1,649,483 98.89 5.9 18,384 NA
3 488,824 488,724 1,667,405 99.97 29.5 462 NA
4 664,278 642,532 1,667,519 99.97 36.3 348 NA
5 1,211,740 1,195,756 1,667,544 99.98 71.8 323 NA
6 2,148,576 2,107,718 1,667,758 99.99 81.7 211 DRS013117
Total reads after trimming are mapped to the reference nucleotides of 1,667,867 bp (NC_000915) and calculated with Genomic Workbench 6.0.1. NA;
not available.
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Adapter sequences were automatically trimmed from the
reads with MiSeq reporter analysis. As shown in Table 1,
the sequencing data from sample 6 of ATCC26695 was
subjected to the quality control analysis.
As a measure of quality control, we determined the
length distribution of sequencing reads, ambiguous base-
content, and quality distribution at each base position
(Additional file 1: Figure S1). This analysis led to the
identification and subsequent removal of several errors in
the raw sequencing data. After trimming, histograms of
sequencing lengths distribution shifted to a shorter
sequence length, and there was no ambiguous base-content.
The mean values of Phred scores were >30 at all base
positions up to 150 bp. Thus, quality control assessment
showed that the entire length from the 150-bp paired-end
reads could be analyzed. The FASTQ file, containing the
trimmed sequences, was used for further analysis.
Coding sequence from ATCC26695 sequencing data
ATCC26695 sample 6 was chosen for further analysis based
on its total number of reads, read quality, and coverage.
Sequencing reads were aligned to the NC_000915 genome
using Genomic Workbench 6.0.1. Analytical procedure was
shown in Additional file 2: Figure S2 as a flow chart.
Despite over two million sequencing reads of ATCC26695,
a total of 211 bp was identified as an assembly gap
to the NC_000915 reference sequence (Table 2). The
detailed assemble gaps were as follows; a total of
51 bp in 48 short insertions, 27 bp in 25 short deletions,
and 133 bp in 4 long deletions. The quality and coverage
of the sequence data was effective to determine the
differences between isolates of a single laboratory
strain. In our sequencing data, seven nucleotides per
genome (1.66 Mb) were different from the reference
nucleotides with over 50% frequency (Table 3).
Taken together, these sequencing data indicated that
over one million sequencing reads had >50-fold average
coverage of the assembled contigs when reads were
mapped to the reference H. pylori genome. Since it was
difficult to identify true single-base and small indelsduring our mapping process, we did not try to identify
any size of indels in further analysis of the clinical isolates.Whole-genome sequencing of 19 clinical H. pylori strains
All H. pylori strains were sequenced with illumina MiSeq.
After triminng, total reads of 7 wild-type (susceptible)
strains ranged from 1.96 million to 5.32 million (Table 4A).
Similarly, total reads of 12 resistant strains ranged from
1.82 million to 10.8 million (Table 4B). After trimming
above-mentioned, sequencing data were mapped to the
ATCC26695 reference genome. Average coverage ranged
from 90.9 to 283.6-fold in susceptibile strains and
from 125.5 to 686.3-fold in resistant strains. These
data indicated that the derived high sequencing depth
of coverage was sufficient to detect high quality SNVs
in the H. pylori genome.Detection of A2146G and A2147G with sequencing reads
Prior to analyzing the target genes in the derived sequence
data, we examined the position of point mutations in 23S
rRNA to identify any false positive variants. Two identical
copies of 23S rRNA (HPr01 and HPr06) are found in the
H. pylori genome [11].
Sequence data of 12 resistant strains mapped to the
ATCC26695 reference genome. The results of two
representative resistant strains, S17 and S26, are
shown in Figure 2. In the S17 strain at position 2146
in the 23S rRNA gene, all sequence reads (479-fold)
had the variant G. Similarly, in S26 at position 2147,
all reads (485-fold) had the variant G. In the other
copy of the 23S rRNA, the same changes were found
in each strain. Sequencing reads of the remaining 10
strains also contained the variant G. The AS-PCR is a
targeted approach for identifying variants at one base-
pair position (i.e., 2146 or 2147), but whole-genome
sequencing can simultaneously detect multiple base-pair
variants with high confidence. In contrast, there was no
variant in the same positions of 23S rRNA genes of 7
CLR-susceptible strains. Representative result of F79
strain was shown in Additional file 3: Figure S3.
Table 2 Assemble gaps of ATCC26695 sequence data from sample 6





Insertion Deletion Start End Insertion: consensus side/
Deletion: reference side
Short insertion
1 1 A 39762 39763 HP0041 → hypothetical protein 63
2 1 G 159581 159582 HP0147 → cytochrome c oxidase, diheme subunit,
membrane-bound (fixP)
89
3 1 C 173256 173257 HP0165 ← hypothetical protein 94
4 1 G 208167 208168 HP0203 → hypothetical protein 85
5 1 C 263286 263287 HP0253 → hypothetical protein 105
6 1 C 331675 331676 2
7 1 T 331678 331679 2
8 1 G 331680 331681 2
9 1 T 331682 331683 2
10 1 G 474218 474219 88
11 1 C 475466 475467 HP0456 → hypothetical protein 53
12 1 C 475645 475646 46
13 1 T 524751 524752 HP0498 → sodium- and chloride-dependent transporter 54
14 1 G 579891 579892 76
15 1 A 626216 626217 57
16 1 A 674290 674291 HP0628 → hypothetical protein 63
17 1 C 683744 683745 HP0636 ← hypothetical protein 54
18 1 G 739962 739963 HP0688 → hypothetical protein 45
19 1 T 745341 745342 HP0694 → hypothetical protein 84
20 1 T 745352 745353 86
21 1 A 745389 745390 95
22 1 T 745429 745430 97
23 2 AG 773423 773424 HP0719 → hypothetical protein 55
24 1 C 787709 787710 HP0732 ← hypothetical protein 62
25 1 G 808800 808801 fliD → flagellar capping protein 57
26 1 C 838354 838355 HP0783 ← hypothetical protein 74
27 1 A 843491 843492 69


















Table 2 Assemble gaps of ATCC26695 sequence data from sample 6 (Continued)
29 1 G 888773 888774 HP0836 → hypothetical protein 98
30 2 AG 915893 915894 HP0863 ← hypothetical protein 112
31 1 A 915897 915898 HP0863 ← hypothetical protein 112
32 1 C 993909 993910 HP0931 → hypothetical protein 109
33 1 G 1026924 1026925 63
34 1 T 1057531 1057532 69
35 1 T 1057599 1057600 59
36 1 T 1077873 1077874 HP1014 → 7-alpha-hydroxysteroid dehydrogenase 83
37 1 G 1207116 1207117 HP1144 → hypothetical protein 74
38 1 C 1207608 1207609 HPr04 ← 16S ribosomal RNA 101
39 1 G 1208482 1208483 HPr04 ← 16S ribosomal RNA 1
40 1 C 1208483 1208484 HPr04 ← 16S ribosomal RNA 2
41 1 T 1256328 1256329 HP1186 → carbonic anhydrase 72
42 1 C 1259151 1259152 113
43 1 A 1264196 1264197 HP1193 → aldo/keto reductase 92
44 1 G 1291618 1291619 HP1216 ← hypothetical protein 74
45 2 GG 1475694 1475695 HPr06 ← 23S ribosomal RNA 1
46 1 C 1511030 1511031 4
47 1 C 1511162 1511163 HPr04 ← 16S ribosomal RNA 83
48 1 C 1511398 1511399 HPr04 ← 16S ribosomal RNA 11
Total 51
Short deletion
1 1 A 25622 58
2 1 C 38695 HP0039m → conjugal plasmid transfer system protein 62
3 2 YC 129158 129159 1
4 1 C 342188 HP0326 → CMP-N-acetylneuraminic acid synthetase 86
5 1 T 426389 HP0413 ← transposase-like protein, PS3IS 18
6 1 A 463967 HP0445 ← hypothetical protein 75
7 1 A 593944 81
8 1 G 650897 HP0609 → hypothetical protein 73
9 1 A 674221 HP0627 → hypothetical protein 47


















Table 2 Assemble gaps of ATCC26695 sequence data from sample 6 (Continued)
11 1 G 745422 98
12 1 C 815405 HP0760 ← phosphodiesterase 41
13 1 C 815420 HP0760 ← phosphodiesterase 48
14 1 R 1027030 73
15 1 G 1049706 58
16 1 G 1071033 HP1009 ← site-specific recombinase 77
17 1 T 1077870 HP1014 → 7-alpha-hydroxysteroid dehydrogenase 87
18 1 G 1081560 HP1018 → hypothetical protein 97
19 1 G 1192591 HP1127 ← hypothetical protein 61
20 1 T 1256382 81
21 1 C 1258321 HP1188 ← hypothetical protein 71
22 1 T 1264200 HP1193 → aldo/keto reductase 91
23 2 NA 1480608 1480609 HP1410 → hypothetical protein 1
24 1 A 1480611 HP1410 → hypothetical protein 1









425976 426036 HP0413 ← transposase-like protein, PS3IS not calculated
3 14 GGATGGGTGCTTTT 1475703 1475716 HPrrnB23S ← transposase-like protein, PS3IS not calculated

































1 130106 T C 217 117 53.9 Gene:
HP0119
2 130111 T G 186 94 50.5 Gene:
HP0119
3 301322 G T 109 108 99.0 Gene:
HP0289
4 1370263 G C 101 99 98.0 Gene: rpmJ
5 1428910 C A 137 104 75.9 Gene:
HP1366
6 1502547 T C 345 184 53.3
7 1502549 A G 345 184 53.3
Total reads and mutated reads indicate the number of reads that passed quality control.
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To identify other possible variants in these clinical isolates,
we next examined genetic variants of four gene clusters of
TolC homologues, which have been associated with
multidrug resistance [23]. To the best of our knowledge,
this is the first survey of H. pylori MDR efflux transporter
variants. During the filtering of uncertain indels and the








177 2,619,844 2,563,352 1,666,155
179 2,291,578 2,269,154 1,560,395
189 2,010,838 1,967,720 1,664,913
F32 5,383,222 5,327,650 1,593,944
F44 3,887,082 3,806,902 1,667,084
F65 4,248,748 4,157,272 1,667,173
F79 3,036,516 3,035,946 1,562,308
CLR-resistant
S1 2,271,944 2,271,890 1,571,448
S2 5,962,628 5,962,428 1,587,965
S4 4,640,490 4,640,330 1,578,524
S8 10,869,516 10,868,918 1,610,753
S13 3,873,394 3,873,000 1,563,976
S16 6,782,392 6,781,628 1,594,857
S17 5,700,038 5,699,336 1,596,480
S22 6,597,254 6,596,450 1,598,844
S23 1,820,652 1,820,436 1,559,100
S26 6,692,038 6,691,390 1,584,702
174 3,004,008 3,003,900 1,580,603
194 6,936,714 6,921,552 1,600,238
Total reads after trimming are mapped to the reference nucleotide of ATCC26695 aof high-quality informative SNVs associated with CDS
variants (Table 5).
In 4 of the 7 susceptible strains (177, 189, F44, and F65),
there were no SNVs in the MDR efflux pump genes. The
other 3 susceptible strains had SNVs in efflux pump genes.
In the CLR-susceptible strain 179, there was a total of 350
SNVs across all four clusters of efflux pump genes. In


























nd calculated with Genomic Workbench 6.0.1.
Figure 2 A2146G and A2147G mutations in the 23S rRNA gene identified by illumina sequencing. The aligned results of sequencing reads
of two CLR-resistant H. pylori strains (S17 and S26) are shown. Along the top, reference nucleotide sequences of NC_000915 (ATCC26695), and
consensus nucleotide sequences of each CLR-resistant strain are shown (black). The lower portion of the sequence viewer shows mapped
sequencing reads (yellow and blue). In 479 reads from S17 strain (left), reference nucleotide A was changed to G at position 2146 in 23S rRNA
(bold faces). Similarly, reference nucleotide A was changed to G at position 2147 in 23S rRNA in 485 reads from S26 (right).
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hp0605-hp0607 cluster, SNVs were certainly observed in all
12 resistant strains. There were significant differences in
SNVs of the hp0605-hp0607 cluster between susceptible
and resistant strains (P < 0.05), but not in the other clusters.
Correlations between the total number of SNVs in
efflux pump clusters and MICs of CLR were examined.
In 10 resistant strains out of 12 isolates, MICs of CLR
were ranged from 4 to 64 μg/ml and exhibited over
1 μg/ml with the criteria of CLR resistance (Table 5).
We found no significant correlation between SNVs and
level of CLR resistance.
To examine the common CDS variant in CLR-resistant
H. pylori, further detailed analysis of the SNVs in the
hp0605-hp0607 cluster was performed (Table 6). In all
CLR-resistant strains, there were no common SNVs in
each hp0605, hp0606, and hp0607 cluster. For the
maximum number of common SNVs, four SNVs of
hp0605 (hefA) were found in 11 out of 12 resistant strains
(91.6%). Of note, one CDS variant of Asn177Thr was in
11 resistant strains. In hp0606 and hp0607, there were no
CDS variants specific to the resistant strains, though
common SNVs in 11 strains (three SNVs in hp0606 and
two SNVs in hp0607) were found. These results indicated
that independent SNVs in the efflux pump genes may
contribute to CLR susceptibility profiles for each strain.
Discussion
Here, we have sequenced whole genomes of H. pylori
isolates by using the massively parallel illumina-basedplatform. This MiSeq platform can generate the largest
amount of paired-end sequence data per sample using a
chip-based bridge amplification procedure followed by
sequencing by synthesis [24]. To determine the adequate
total reads and average coverage per sample, six different
sequencing data sets from ATCC26695 have been analyzed.
We have observed that the amount of sequencing reads
after trimming was directly proportional to the average
coverage from 4.2- to 81.7-fold. Genome depth is a major
factor that determines the ability to reconstruct genome
sequences and detect genetic variants with low error rate
[25]. To reach the necessary balance between the number
of total reads and average coverage, over one million reads
with depth of over 70-fold is sufficient for identification of
genetic variants in the bacterial genome of 1.6 Mb [26,27].
However, we could not create a complete gap closure to
the reference H. pylori genome with sufficient sequencing
coverage. Illumina sequencing technique produces large
amounts of short overlapping reads from the target
genome [28]. The first task of analysis is to assemble these
reads to larger regions of the bacterial genome. Since
there is an assembly gap, we have reduced the number of
false positive candidates and did not try to identify inser-
tions or deletions (indels) of any size in the analysis.
Sequencing-based indels detection methods are not
well-established even utilizing paired-end data [29],
and the reliable detection of indels is complex. In
addition, under our approach of reference based assembly,
it is difficult to detect true indels due to small assembly
gaps even when sequencing the reference genome. Thus,
Table 5 SNVs of multidrug resistant efflux pump genes and MICs of CLR




















hp1487 hp1488 hp1489 Total
CLR-susceptible
177 - 0 0 0 0 0 0 0 0 0 0 0 0 0
179 - 29 12 70 51 13 3 22 16 47 30 26 31 350
189 - 0 0 0 0 0 0 0 0 0 0 0 0 0
F32 - 48 20 76 83 24 27 0 0 0 0 0 0 278
F44 - 0 0 0 0 0 0 0 0 0 0 0 0 0
F65 - 0 0 0 0 0 0 0 0 0 0 0 0 0
F79 - 39 15 49 55 16 30 0 0 0 0 0 0 204
CLR-resistant
S1 32 32 17 51 55 9 25 23 18 61 23 13 27 354
S2 32 50 18 74 0 0 0 0 0 0 0 0 0 142
S4 32 39 18 67 55 16 26 0 0 0 0 0 0 221
S8 4 44 19 67 0 0 0 0 0 0 0 0 0 130
S13 16 52 21 80 76 22 31 0 0 0 0 0 0 282
S16 16 54 23 81 0 0 0 0 0 0 0 0 0 158
S17 32 48 19 87 0 0 0 0 0 0 0 0 0 154
S22 64 46 16 69 0 0 0 0 0 0 0 0 0 131
S23 16 1 16 21 14 2 8 38 10 71 23 19 42 265
S26 32 55 24 83 0 0 0 0 0 0 0 0 0 162
174 - 40 11 55 58 19 34 26 10 52 27 19 47 398
194 - 25 7 34 48 15 18 0 0 0 0 0 0 147
Statistics
P value 0.011 0.017 0.038 NS NS NS NS NS NS NS NS NS NS
95% CI 6.1-41.7 2.5-18.8 2.5-69.9
NS; not significant.
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on SNVs of H. pylori coding sequence.
In the present study, we have applied the AS-PCR
method to detect mutations in the 23S rRNA gene of H.
pylori, in which these mutations were perfectly identical
in all sequencing reads at the AS-PCR assayed position.
AS-PCR utilizes allele-specific primers such that the
second nucleotide from the 3′ end is designed to
match the site of the point mutation [30]. This AS-PCR
assay is well-established to definitely identify whether
a H. pylori strain is sensitive or resistant to CLR
[31,32]. Our analysis is a successful comparison between
point mutations detected by both AS-PCR and short-read
sequencing. Currently, there are few studies in which
genetic mutations of antimicrobial resistance identified
with sequencing data are consistent with recorded variants
[33,34]. In addition, next-generation sequencing could
clearly distinguish a point mutation in the 23S rRNA gene
in the H. pylori genome.
To provide future advances for treatment of H. pylori
infections, we need to know whether variants ofMDR efflux pump genes rely on drug resistance as a
species-dependent intrinsic factor. The resistance-
nodulation-cell division (RND) family is grouped into
MDR efflux pumps in gram-negative bacteria [35].
AcrB protein, a member of the RND family, forms a
homotrimer with an outer membrane protein (TolC)
and a periplasmic membrane fusion protein (AcrA)
[36,37]. In H. pylori, two TolC homologs, hp0605 and
hp1489, have been identified on the basis of structural
similarities with outer membrane efflux protein formed
RND domains [38]. In addition, three RND efflux systems,
each of which consists of an accessory protein of
translocase, have been identified as TolC homolog
[39]. Now, four gene clusters of efflux pump systems
(hp0605-hp0607, hp0971-hp0969, hp1327-hp1329, and
hp1489-hp1487) are identified in H. pylori [23] and
possibly contribute to resistance to antimicrobials,
which resemble the situation in other bacteria [40].
Expression analysis in clinical isolates has shown the
importance of efflux pump genes to antimicrobial
agents. In response to the exposure of metronidazole,
Table 6 SNVs of hp0605-hp0607 cluster in 12 CLR-resistant H. pylori
Locus tag HP0605 (NP_207400.1)
Annotation hypothetical protein
Coding sequence c.530A > C c.546A > G c.804 T > C c.1365 T > C
Amino acid p.Asn177Thr No No No
Nucleotide positiona 641828 641844 642102 642663
Strain Count reads/
Total reads
Frequency (%) Count reads/
Total reads
Frequency (%) Count reads/
Total reads
Frequency (%) Count reads/
Total reads
Frequency (%)
S1 179/180 99.4 181/181 100 140/141 99.3 107/107 100
S2 373/373 100 392/394 99.5 319/320 99.7 295/295 100
S4 212/213 99.5 219/221 99.1 212/214 99.1 204/205 99.5
S8 507/508 99.8 530/532 99.6 478/479 99.8 503/506 99.4
S13 218/218 100 225/225 100 169/170 99.4 179/179 100
S16 343/343 100 371/371 100 325/325 100 312/313 99.7
S17 266/266 100 306/306 100 185/186 99.5 246/246 100
S22 328/328 100 348/348 100 299/299 100 287/289 99.3
S23 - - - -
S26 341/341 100 368/368 100 321/321 100 310/311 99.7
174 123/123 100 124/124 100 114/114 100 151/151 100
194 305/306 99.7 324/324 100 341/343 99.4 231/232 99.6
Locus tag HP0606 (NP_207401.1)
Annotation membrane fusion protein MtrC
Coding sequence c.99 T > C c.105A > G c.192A > G
Amino acid No No No
Nucleotide position 642841 642847 642934
Strain Count reads/
Total reads
Frequency (%) Count reads/
Total reads
Frequency (%) Count reads/
Total reads
Frequency (%)
S1 140/140 100 129/129 100 139/140 99.3
S2 340/340 100 324/324 100 383/385 99.5
S4 194/194 100 192/193 99.5 221/223 99.1
S8 496/498 99.6 472/473 99.8 505/506 99.8
S13 203/203 100 194/194 100 -
S16 329/331 99.4 316/317 99.7 335/335 100
S17 233/233 100 230/230 100 272/273 99.6


















Table 6 SNVs of hp0605-hp0607 cluster in 12 CLR-resistant H. pylori (Continued)
S23 109/109 100 105/105 100 110/110 100
S26 323/325 99.4 311/312 99.7 331/331 100
174 137/138 99.3 126/127 99.2 137/138 99.3
194 - - 299/301 99.3
Locus tag HP0607 (NP_207402.1)
Annotation acriflavine resistance protein AcrB
Coding sequence c.1341T>C c.39A>G
Amino acid No No
Nucleotide position 644800 643498
Strain Count reads/Total reads Frequency (%) Count reads/Total reads Frequency (%)
S1 159/160 99.4 123/124 99.2
S2 345/347 99.4 280/280 100
S4 284/286 99.3 182/182 100
S8 585/586 99.8 431/432 99.8
S13 227/228 99.6 164/164 100
S16 425/425 100 295/295 100
S17 317/317 100 198/198 100
S22 346/347 99.7 273/275 99.3
S23 104/104 100 106/106 100
S26 419/419 100 295/295 100
174 113/113 100 -
194 - 342/344 99.4
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been shown to increase, indicating the relation with
drug resistance in H. pylori [41]. More recently, exposure
of CLR in vitro has induced natural transformation to
the genome of strain 26695, which resulted in the
point mutation of acrB (hp0607) with whole-genome
sequencing [42]. To extend these previous findings,
this study highlights the importance of MDR efflux
pumps of H. pylori derived from active infections.
This study has indicated a link between specific variants
of efflux pump genes and the CLR-resistant phenotype.
The exact mechanism underlying these genetic mutations
is unclear. Possible mechanisms of intrinsic drug resist-
ance involve decreased drug uptake or increased drug
efflux [39]. Knockout mutants for each of hp0605 and
hp0971 have displayed drug susceptibility profiles to
metronidazole, novobiocin, and sodium deoxycholate [23].
Indeed, we have found that specific mutations in hp0605,
hp0971, and the other variants in efflux pump systems are
significant in CLR-resistant strains. Whole-genome sequen-
cing data include vast amounts of additional information
that are currently unavailable from small scale analysis.
Variants in efflux pump genes have a possible effect on the
association with drug susceptibility in clinical isolates.
Conclusions
We have provided successful validation of genotypic pre-
diction for antimicrobial resistance with the PCR-based
approach and highlighted the potential of whole-genome
sequencing in the analysis of H. pylori isolates. These se-
quencing data have emphasized the significant function of
the variants of efflux pump genes in CLR-resistant strains.
Since we have been conservative in our analysis to focus
on only well-validated SNVs in limited parts of the bac-
terial genome, further analyses (e.g., indels, short repeats,
rearrangements, and phylogenetics) with whole genome
methods, such as gap closure, could provide more detailed
discrimination of the drug resistant H. pylori isolates.
Methods
H.pylori samples
Nineteen H. pylori clinical isolates were separated from
gastric epithelium biopsy tissues during upper gastroduo-
denal endoscopy at Okinawa Prefectural Chubu Hospita,
and Kobe University Hospital. All patients gave written in-
formed consent for use of their samples for the present
study, and this study was performed according to the prin-
ciples of the Declaration of Helsinki. The major reference
strain, ATCC26695 (NC_000915), was also used.
H.pylori culture
Gastric biopsy specimens were transferred onto a Trypti-
case soy agar II (TSA-II)-5% sheep blood plate and cultured
under microaerobic conditions (O2, 5%; CO2, 15%; N2,80%) at 37°C for 5 days. One colony was picked from each
primary culture plate, and seeded onto a fresh TSA-II
plate. A few colonies were picked from each plate and
transferred into 2 ml of brucella broth liquid culture
medium containing 10% fetal calf serum and cultured for
3 days. A part of the liquid culture was stored at −80°C in
0.01 M PBS containing 20% glycerol. H. pylori DNA
was extracted from the pellet of the liquid culture by
the protease-phenol-chloroform method, suspended in
300 μl of TE buffer, and stored at 4°C until AS-PCR
and sequencing.
Antibiotic susceptibility testing
To determine the MICs of CLR, CLSI agar dilution
method was used [43]. Briefly, two-fold dilutions of CLR
were prepared in Muller-Hinton agar (Becton Dickinson,
MD) with 5% sheep blood. Following the preparation of
H. pylori suspension in physiological saline adjusted to a
2.0 McFarland standard, a 1 to 3 μl inoculum was spotted
on agar plate. Following incubation at 37°C for 72 h under
microaerophilic atomosphere, the MICs of CLR were
established as the drug concentration showing no growth.
Allele-specific PCR (AS-PCR) for 23S rRNA gene mutations
Analysis of alleles with point mutations in 23S rRNA
(A2146G and A2147G) was performed according to previ-
ous reports [31,32]. The allele-specific primer sequences
are listed in Additional file 4: Table S1. The PCR mixture
was contained 100 ng of DNA with 10 × buffer 2.5 μl,
2 mM dNTP 2.5 μl, 25 mM MgCl2 1 μl, 10 pmol primer
mixtures, and 0.5 U KOD-plus DNA polymerase (TOYOBO,
Osaka, Japan). Then, mixture was up to 25 μl with dis-
tilled water. The PCR condition was as follows; 94°C for
2 min and 35 cycles of 94°C for 15 sec, 60°C for 30 sec,
and 68°C for 30 sec, followed by 68°C for 2 min. PCR
products were determined by 4% agarose gel electro-
phoresis. The gels were stained with ethidium bromide to
determine the product size. ATCC26695 and J99 were
used as control strains for the AS-PCR.
Preparation of genomic DNA and whole-genome
sequencing
Total DNA of H. pylori isolated from patients and the
reference ATCC26695 were sequenced. Bacterial DNA was
extracted with DNeasy blood and tissue kit according to
manufacturer’s guideline (Qiagen, Hilden, Germany). DNA
concentration of each sample was measured with Qubit
dsDNA HS assay kit (Q32851; Invitrogen, Carlsbad, CA).
An <500-bp DNA library of H. pylori strains (50 ng or
1 ng) was prepared by using Nextera DNA Sample Prep Kit
(illumina, San Diego, CA) or Nextera XT DNA Sample
Prep Kit (illumina). According to the manufacturer’s in-
structions (version May 2012), DNA was uniformly sheared
into 500-bp portions with these kits, and DNA libraries
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then run on MiSeq sequencer (illumina) with Reagent kit
(300 cycle, paired-end). Fluorescent images were analyzed
using the MiSeq Control Software, and FASTQ-formatted
sequence data was created using MiSeq Reporter Analysis.
Sequence reads mapping and SNVs detection
For used sequence data, read quality was selected at Q30
over 80% followed by the suggestion of illumina. After qual-
ity check and data trimming, Genomics Workbench 6.0.1
(CLC bio, Aarhus, Denmark) was used to assemble the
sequence. The read mapping module was termed as CLC
Assembly Cell 4.0, which was based on an uncompressed
Suffix-Array representing the entire reference genome in a
single data structure (White paper on CLC read mapper;
October 10, 2012). Sequence reads were mapped against
the reference genome of ATCC26695 (NC_000915), and
single nucleotide variants (SNVs) were identified with prob-
abilistic variant detection modules with default parameters
and minor modifications in the mapping algorithm. Variant
detection was set to 1 in Genomics Workbench 6.0.1. To
exclude false-positive variants resulting from sequencing
errors, we selected variants presented in > 99.0% of mapped
reads with minimum coverage of 100. Insertions and dele-
tions were also discarded. During this process, a set of
high confidence variants was generated.
Variants of MDR efflux pumps in clinical H. pylori strains
Generally, in gram-negative bacteria, the resistance-
nodulation-cell division (RND) family is representative of
MDR efflux pumps, which includes the AcrAB-TolC sys-
tem in Escherichia coli [35]. In the H. pylori 26695 genome,
four gene clusters of TolC homologues, hp0605-hp0607
(hefABC), hp0971-hp0969 (hefDEF), hp1327-hp1329
(hefGHI), and hp1489-hp1487, have been indicated as MDR
efflux pumps based on sequence similarity to other bacter-
ial species [23] and their gene expression patterns [16].
Statistical analysis
The associations between the genetic variants of efflux
pump genes and the phenotype of CLR resistance were
analyzed with Student’s t-test. Correlation coefficient
between the genetic variants and MICs of CLR was
also calculated, and the 95% confidence interval (CI)
was used to estimate the risk. A P value of <0.05 was
accepted as statistically significant. The SPSS statistical
software package version 20.0 (SPSS, Inc., Chicago, IL)
was used for all statistical analyses.
Nucleotide sequence accession number
All sequence reads of 19 clinical isolates and ATCC26695
have been deposited in the DNA Data Bank of Japan
Sequence Read Archive (http://www.ddbj.nig.ac.jp/index-
e.html) under accession number DRA001250.Additional files
Additional file 1: Figure S1. Sequencing quality control of ATCC26695
sequence data from sample 6. ATCC26695 sequence data from sample 6
with 2,148,576 reads was subjected to the quality control analysis. The
length distribution of sequencing reads (A), ambiguous base-content (B),
and quality distribution at each base position (C), are shown.
Additional file 2: Figure S2. Flow chart of sequencing reads analysis.
Additional file 3: Figure S3. Sequence of 23S rRNA gene at 2146 and
2147 position in CLR-susceptible F79 strain.
Additional file 4: Table S1. Allele specific-PCR primer sequences.
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